1. Introduction, purpose of this Standard Operating Procedure (SOP)
|
|
- Jean Williams
- 5 years ago
- Views:
Transcription
1 SOP-CTN-001- Clinical Trial Network - General Organisation and Principles European Society of Anaesthesiology Details Document Type Document name Ref # Version Effective from Review date Owner Prepared by Reviewed by Approved by Superseded documents Relevant regulations/legislation/guidelines/reference Standard Operating Procedure (SOP) ESA Clinical Trial Network - General Organisation and Principles SOP-CTN-001 Draft v 1.0 dated 17/Dec/ /Dec/ /Dec/2014 ESA Clinical Trial Network, ESA Secretariat Brigitte Leva Sandrine Damster, ESA Research Committee (RC) Member: Wolfgang Buhre, George Shorten ESA RC Chair: Andreas Hoeft none 1* ICH Guidelines 2* CDISC : glossary of terms 3* DOH 4* EU Directives 5* HMSO 6* FDA Change History Date Version Number Change details Approved by 1. Introduction, purpose of this Standard Operating Procedure (SOP) The present standard operating procedure aims to define and clarify the general principles, organisation, and management of the European Society of Anaesthesiology Clinical Trial Network with written instructions to achieve uniformity. The SOP refers to the guidelines for Good Clinical Practice and regulations referenced above. The SOP describes the general roles and responsibilities of the CTN and its staff. This document describes the benefits of collaboration with the ESA CTN (financial support, CTN support package, and sponsorship). The present SOP further details the call for applications and application steps. 2. Summary The European Society of Anaesthesiology (ESA) Clinical Trial Network (CTN) provides an infrastructure for Institutions, clinicians and scientists allowing to work collaboratively across international borders to improve the care of patients in the field of Anaesthesiology, Intensive Care, Peri-Operative Medicine, Emergency Medicine and Pain Medicine. International networks all over the world have demonstrated the advantages of collaboration to address and answer clinically relevant research questions. Long-term collaborative relationships within research, education and clinical practice require dedicated resources and infrastructure enabling access to the entire clinical community. The aim of the ESA Clinical Trial Network (CTN) is to build such a collaborative network. 3. Glossary Standard Operating Procedures (SOP) are detailed, written instructions to achieve uniformity of the performance of a specific function. SOPs form the basis on which Quality Systems and Processes are conducted and monitored against. (ref. 1* ICH) Interventional Clinical Study: Clinical Study in which, a drug, device, therapy or process under investigation has an effect on an outcome of interest: e.g. quality of life, efficacy, safety, and pharmacoeconomics. (ref. 2* CDISC) Page 1 of 8
2 SOP-CTN-001- Clinical Trial Network - General Organisation and Principles European Society of Anaesthesiology Observational Clinical Study: Clinical Study without any intervention. Researchers observe participants and keep track of their health to measure individual and cohort outcomes. Specific drugs are not used in this type of study. Sponsor: - The EU Directive 2001 defines a sponsor as an individual, company, institution or Organisation which takes responsibility for the initiation, management and/or financing of a clinical trial. (ref. 4* EU-DIRECTIVE 2001/20). - UK Department of Health defines Sponsor as the Responsible for ensuring that arrangements are in place for the management, monitoring and financing of research (ref. 3* DOH 2001) - Definition of Sponsor by UK Her Majesty's Stationery Office (HMSO) is the person who takes responsibility for the initiation, management and financing (or arranging the financing) of that trial (ref. 5* HMSO, SI: ) - USA Food and Drug Administration in its Code of Federal Regulations Title 21 (ref. 6* FDA21 CFR 812.3).distinguishes the following: Sponsor: A person who initiates, but who does not actually conduct, the investigation, i.e., the investigational device is administered, dispensed, or used under the immediate direction of another individual. A person other than an individual that uses one or more of its own employees to conduct an investigation that it has initiated is a sponsor, not a sponsorinvestigator (see next definition), and the employees are investigators. Sponsor-investigator an individual who both initiates and actually conducts, alone or with others, an investigation, i.e., under whose immediate direction the investigational device is administered, dispensed, or used. The term does not include any person other than an individual. The obligations of a sponsor-investigator include both those of an investigator and those of a sponsor. Investigator an individual who actually conducts a clinical investigation, i.e., a person under whose immediate direction the investigational product is administered, dispensed, or used, provided that the investigation involves a subject. In the event of an investigation conducted by a team of individuals, the investigator is the responsible leader of that team. Page 2 of 8
3 SOP-CTN-001- Clinical Trial Network - General Organisation and Principles European Society of Anaesthesiology 4. ESA Clinical Trial Network staff, overview of responsibilities ESA ESA Research Commitee ESA Clinical Study Coordinator Study Chief Investigator Sponsor for Observational study = ESA National Coordinators Study Steering Committee Sponsor for Interventional Study = Institution of CI Local Coordinators Other Site staff (clinicians,nurses, etc.) ESA Research Committee (RC): The Research Committee may determine areas of particular scientific interest for a specific call and assumes responsibility for selecting studies through a competitive process, facilitates recruitment of centres (through the ESA CTN and personal contacts). If required, the RC may nominate a Data Safety Monitoring Board. Study Chief Investigator (CI): A Registered Physician who has overall responsibility for the Trial and who takes responsibility for: - Submission of a project to ESA RC including discussion of the literature, time-line and financial description. This submission is usually made on behalf of the Steering Committee. - Submission of the protocol for ethical approval and other necessary regulatory bodies for approvals. - Identification of centres willing to participate in the study. - Advancement of the project to successful conclusion including publication in a peer reviewed journal or journals. - Acknowledging ESA in all publications and presentations arising from the work. Study Steering Committee: A group of scientists which typically comprises at least five but no more than ten persons. The Committee actively contributes in the study design, conduct, data analysis and dissemination of study findings. Sponsor: An individual, company, institution, or Organisation which takes responsibility for the initiation, management, and/or financing of clinical trial. (ref. 1* ICH) See Glossary above and Sponsorship and collaboration section 6.3 for details. ESA Clinical Study Coordinator: The person, who handles most of the administrative responsibilities of a clinical study. The Clinical Study Coordinator is located at the ESA Secretariat Office established in Brussels and facilitates all aspects of trial administration, working in close collaboration with the Study Steering Committee to finalise the study documents and with the national co-ordinators and study centres to disseminate information. National Coordinator (NC): The person who is responsible for co-ordination of investigators and sites in different participating centres in his/her country. See guidance in section 8 Local Coordinator: Individual member of the study team designated and supervised by the principal investigator at a trial site (e.g. hospital) to perform study related procedures e.g. patient consent, randomisation, data collection, data return, etc. See guidance in section 8 Page 3 of 8
4 5. General Principles of the ESA CTN Aim Authorship Rules General Principles Patient Care Data Property 1. ESA CTN Aim The aim of the European Society of Anaesthesiology Clinical Trial Network is to facilitate, to integrate and to support clinical research conducted by members or research groups of the ESA or collaborating individuals or groups at an international level. The ESA CTN is managed by the ESA RC (Research Committee), and its actions and activities are reported to the ESA Board by the ESA RC Chair. 2. ESA CTN for Patient Care Organisation committed to enhance patient care through research and education, and will help to raise the long-term objectives of the Society. All members of the ESA CTN agree to abide by the principles and obligations set out below. All contributors to and participants in the ESA CTN will agree to abide by the principles of ethical conduct in research and good clinical practice. They will act in the best interests of their patients and of the scientific community. 3. ESA CTN Studies Data Property The CTN is part of the ESA. For each Study, the study protocol will detail the Sponsorship and the data ownership policy. For ESA sponsored studies, the intellectual property of the data remains under the responsibility of the ESA/ESA RC In case of collaborative studies with other societies (ESICIM, etc.), the ownership of data The Chief Investigator of the chosen trial is responsible for approval, monitoring, and financial issues of the research project. He/she reports to the chair of the ESA RC. If needed, an independent evaluation of feasibility of a large-scale project (and evaluation of adequacy of use of financial resources) will be requested from external reviewers experts in epidemiology or clinical trials. 4. ESA CTN Authorship Rules The Chief Investigator and the ESA RC agree on authorship order and/or criteria governing authorship in advance. This must be described in the study protocol. Each study should include the name of the network in the list of authors. Including all members of the project Steering Committee is not mandatory. Collaborators responsible for recruitment of the greatest number of patients and those who contribute at each step of the project (designinclusion-analysis-writing) should be prioritised. Page 4 of 8
5 6. Clinical Trial Network benefits Financial Sponsorship Benefits Administrative Coordination The ESA offers the following benefits for a period of at least 1 year to Research investigators and Research groups/steering Committee. 1. Financial support A CTN grant up to 30,000 is provided for Study costs. This grant is used for electronic data capture, statistical advice, publication, and to support traveling costs. For meetings, ESA Committee procedures are followed with agenda and minutes recorded. Meetings should occur at reasonable costs, mainly at the ESA Brussels Secretariat or at other ESA meetings such as Euroanaesthesia Congress. The ESA is responsible for covering the costs of the hosting facility, if needed. In this respect, the ESA can also facilitate video conferencing platforms. 2. Administrative and Coordination support package Support includes: - Access to the ESA members database; potential partner centres that constitute the first core of the ESA CTN (access via the ESA Secretariat); - Entitlement to display the ESA CTN logo together with the following sentence: Endorsed by the ESA Research Committee of the European Society of Anaesthesiology on their documentation, s and websites. The ESA Board and the ESA RC must be informed of any promotional material embedding the ESA CTN logo; - Dedicated section on the ESA website for study description, study documents and communication between researchers; - Facilities of the ESA Headquarters for meetings of the Chief Investigator with the study Steering Committee and National coordinators (if needed); - Space in the ESA newsletter for promoting the study; - Annual Congress: Provision of a meeting room during the ESA Annual Congress, subject to space availability, opportunity to promote the project and display documentation at the ESA booth whenever available. - Teleconference calls (number and extent to be defined upon study); - Study Coordination: ESA Staff dedicated to study coordination will support the Chief Investigator in: The preparation and review of key study documents: Study protocol, patient case report form, study guidelines and forms Administrative follow up: filling of applicable Ethics approval and documents Preparation of technical facilities for Data capture as well as electronic Case report Form (CRF) Page 5 of 8
6 Follow up of participants: Call for centres, sending information letters to the sites (pre, during, post recruitment). For details on call for centre process, please refer to GUI- CTN-001 in section 8. Data handling and data cleaning support Study Report and archiving support 3. Sponsorship and collaboration: - Current regulations require that an Investigator-driven clinical trial (IDCT) has a single sponsor an agency or organisation that takes legal responsibility and liability for the trial. Many Organisations are unwilling to undertake the role of sponsor at a pan- European level for multinational trials. Widely varying regulations and laws on liability between countries makes sponsorship difficult to define. This is one main difference in Europe between academic and pharmaceutical companies, the latter being able to take pan-european sponsorship, while for the former it is extremely difficult. - In addition there is no consistent approach to the sponsorship of trials that are not investigating IMPs (Investigational Medicinal Products) in Europe. - In view of the above consideration the following has been decided for ESA CTN: - For observational studies, the ESA can act as legal sponsor. It depends on the individual study and will be documented in the study protocol. In the case that ESA is acting as Sponsor, the ESA Study Coordinator will ensure study registration. In the case that the local academic institution of the Chief Investigator would is sponsor, the CI will ensure that the study is registered and updates provided through the clinicaltrials.gov website. - For Interventional studies, the ESA cannot act as the sponsor; in this case the sponsor will be the local academic institution of the CI and ESA will act as a funding collaborator. - If required, the ESA can facilitate contacts with potential partners, and will also support fund raising if appropriate (i.e. collaboration with national funding agencies and industrial partners). - If required, the ESA can support in grant applications and assist with preparation of applications to the European Commission or to other funding bodies. Page 6 of 8
7 7. Call for Studies Application Process: Who can submit an Application? Selection Steps Application Process What kind of project can be submitted? Application Steps 1. Who can submit an Application? Every physician can apply for support by the ESA CTN. Non ESA members health care professionals are entitled to present proposals. 2. What kind of project can be submitted? The ESA CTN targets scientific and educational research activities, which are of interest in the field of Anaesthesiology, Intensive Care, Emergency Medicine and Pain Medicine. There are no restrictions with respect to the scale of a study. The ESA actively promotes observational and interventional studies which benefits from a large population. Sub-studies: In principle, applications for sub-studies within a main study are possible and can be done by every participating centre. The Chief Investigator and the Steering Committee are responsible if a sub-study is feasible or not. The ESA RC Committee must be informed in case of sub-study is performed. 3. Application Steps Call for Studies proposals is open when agreed by the ESA RC members during the Research Committee meetings. A Call for Study proposals is published on the ESA website, Newsletter and enews etc. at least 3 months before the deadline for application. Full application is done using the for ESA Call For Study Proposal Form Research Grants. The chief investigators will present their study proposal. The study proposal will be sent to the ESA Research Secretariat. Late applications will not be accepted. 4. Selection Steps Evaluation and selection of proposals will be carried out by the ESA RC. The ESA RC is responsible for communication with successful applicants. One to two members of the RC are selected for in depth evaluation of the proposal (literature review, evaluation of methods, relevance of study endpoints, plausibility of study expected effects and power analysis). During the RC meeting, the proposals are discussed in depth by all members, after presentation of critical analysis by 2 pre-selected members. A decision is taken (agreement / rejection / postponed and need for further information). As deemed appropriate, one or more research projects will be recommended for grant. The ESA Board must ratify the grant and approve the final budget before the grant is awarded. After approval by the Board, the Principal Investigator of the successful proposal will be required to become an ESA member in order to receive the ESA CTN grant. Page 7 of 8
8 8. Related documents and checklists 8.1 GUI-CTN-001 Call for Centres Guidelines 8.2 GUI-CTN-002 Local Coordinator Role Guidelines 8.3 GUI-CTN-003 National Coordinator Role Guidelines 8.4 GUI-CTN-004 CTN Cost Reimbursement Guidelines 8.5 Call For Study Proposal Form 8.6 How to Fill in the Call For Study Proposal Form Page 8 of 8
1. Introduction, purpose of this Standard Operating Procedure (SOP)
Details Document Type Document name Ref # Version Effective from Review date Owner Prepared by Reviewed by Approved by Superseded documents Relevant regulations/legislation/guidelines/reference Standard
More informationSOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup
SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup Authorship Team: Leanne Quinn for Joint SOP Group on Trial Processes (viz Ian Russell, Anne Seagrove, Jemma Hughes, Yvette
More informationDocument Title: Document Number:
including Document Title: Document Number: Version: 2.0 Ratified by: Committee Date ratified: 25/01/2018 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel Fay Corporate
More informationEuropean network of paediatric research (EnprEMA)
17 February 2012 EMA/77450/2012 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM 005 SOP category: Trial Management Version number: 03 Version date: 19 December
More informationHertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust
Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust STANDARD OPERATING PROCEDURE FOR RESEARCH Definition of Responsibilities for Externally
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM-005 SOP category: Trial Management Version number: 04 Version date: 10 July
More informationEuropean network of paediatric research (EnprEMA)
20 December 2010 EMA/770017/2010 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationStandard Operating Procedures
Standard Operating Procedures 5.7 Site Initiation Version V1.0 Author/s Approved B Fazekas, S Kochovska D Currow Effective date 30/09/2017 Review date 30/09/2019 DO NOT USE THIS SOP IN PRINTED FORM WITHOUT
More informationMethods: Commissioning through Evaluation
Methods: Commissioning through Evaluation NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number End of Study Report SOP-RES-027 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Natalie
More informationRESEARCH GOVERNANCE GUIDELINES
RESEARCH GOVERNANCE GUIDELINES STUDY STEERING COMMITTEE (SSC) or TRIAL STEERING COMMITTEE (TSC) This document is designed to provide information and guidance relating to Steering Committees and Data Monitoring
More informationEuropean network of paediatric research (Enpr-EMA)
23 January 213 EMA/25452/213, Rev 1 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationResearch Policy. Date of first issue: Version: 1.0 Date of version issue: 5 th January 2012
Research Policy Author: Caroline Mozley Owner: Sue Holden Publisher: Caroline Mozley Date of first issue: Version: 1.0 Date of version issue: 5 th January 2012 Approved by: Executive Board Date approved:
More informationCorporate. Research Governance Policy. Document Control Summary
Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:
More informationSubmission of a clinical trial for access to ECRIN services Notice to the Applicant
Submission of a clinical trial for access to ECRIN services Notice to the Applicant BEFORE SUBMITTING YOUR PROTOCOL Please, contact the European Correspondent (EuCo) in your country. The list of EuCos
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationSuggestions for Modification of the Clinical Trials Directive ELN Annual Meeting 01 February 2011
Suggestions for Modification of the Clinical Trials Directive ELN Annual Meeting 01 February 2011 European Medical Research Councils Dr Kirsten Steinhausen 1 ESF Member Organisations ESF is an independent
More informationScientific Advice and Protocol Assistance at the EMEA
Univ.-Doz. Dr. Bernhard Fischer, MBA P.O. Box 4, A-1097 Vienna, Austria Phone: +43-(0)664-1432919 Fax: +43-(0)664-1477280 Mail: biotechconsulting@aon.at URL: www.biotechnologyconsulting.eu Regulatory Affairs
More informationThis Agreement dated DD/MM/YYYY (the Effective Date ) is between
Clinical Trial Delegation of Sponsorship Responsibilities to Chief This Agreement dated DD/MM/YYYY (the Effective Date ) is between Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7
More informationClinical Practice Guideline Development Manual
Clinical Practice Guideline Development Manual Publication Date: September 2016 Review Date: September 2021 Table of Contents 1. Background... 3 2. NICE accreditation... 3 3. Patient Involvement... 3 4.
More informationStandard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol
Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH SETTING FOR STAFF ISSUE Trustwide Chief and Principal Investigators of research sponsored and/or hosted by UHBristol Oversight of research
More informationPolicy for Access to MINDACT Biological Materials and Data
Policy for Access to MINDACT Biological Materials and Data Public Version 8 Contents 1. Introduction... 3 2. Glossary... 3 3. Governance and responsibilities... 5 4. General principles... 5 5. Review Procedures...
More informationCOMMISSIONING SUPPORT PROGRAMME. Standard operating procedure
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE COMMISSIONING SUPPORT PROGRAMME Standard operating procedure April 2018 1. Introduction The Commissioning Support Programme (CSP) at NICE supports the
More informationGuidance for the Tripartite model Clinical Investigation Agreement for Medical Technology Industry sponsored research in NHS Hospitals managed by
Guidance for the Tripartite model Clinical Investigation Agreement for Medical Technology Industry sponsored research in NHS Hospitals managed by Contract Research Organisations (CRO mcia, 2011 version)
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationDocument Title: GCP Training for Research Staff. Document Number: SOP 005
Document Title: GCP Training for Research Staff Document Number: SOP 005 Version: 2 Ratified by: Version 2, 04/10/2017 Page 1 of 13 Committee Date ratified: 26/10/2017 Name of originator/author: Directorate:
More informationCALL FICHE 1 SCIENCE IN SOCIETY 2009
CALL FICHE 1 SCIENCE IN SOCIETY 2009 Call identifier: FP7-SCIENCE-IN-SOCIETY-2009-1 Date of publication: Wednesday 3 September 2008 Deadline: Tuesday 13 January 2009 at 17.00.00, Brussels local time. Indicative
More informationOverview ICH GCP E6(R2) Integrated Addendum
2017 Biomedical Research Alliance of New York LLC CITI Program is a division of BRANY Overview ICH GCP E6(R2) Integrated Addendum Introduction On 15 December 2016, the International Council for Harmonistion
More informationMEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC
MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Memorandum of understanding between MHRA, COREC and GTAC 1. Purpose and scope 1.1 Regulation 27A of the Medicines for Human Use (Clinical Trials)
More informationERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants
Share. Care. Cure. ERN Assessment Manual for Applicants 2. Technical Toolbox for Applicants An initiative of the Version 1.1 April 2016 1 History of changes Version Date Change Page 1.0 16.03.2016 Initial
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More information20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice
20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice Nursing Research/ Evidence-Based Practice Checklist (Version 31 January 2012) Specify the date in the left column when
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationRESEARCH GOVERNANCE POLICY
RESEARCH GOVERNANCE POLICY DOCUMENT CONTROL: Version: V6 Ratified by: Performance and Assurance Group Date ratified: 12 November 2015 Name of originator/author: Assistant Director of Research Name of responsible
More informationGuidance for applicants requesting scientific advice
7 December 2017 EMEA/CVMP/SAWP/172329/2004 Rev. 5 Veterinary Medicines Division Introduction The Scientific Advice Working Party (SAWP-V) of the Committee for Medicinal Products for Veterinary Use (CVMP)
More informationThe Northern Ireland Clinical Research Network. Guidance Document
The Northern Ireland Clinical Research Network Guidance Document Document Page NICRN Steering Committee Terms of Reference 2 NICRN Clinical Management Group Terms of Reference 4 NICRN Clinical Lead Role
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More informationGovernance %%.4- r2&% Queen s University Belfast. Standard Operating Procedure Research Governance. r2.aoc7. Research and Enterprise
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Delegation of Responsibilities SOP Reference QUB-ADRE-005 Date prepared 23 June 2008 Number: Version
More informationStandard Operating Procedure Research Governance
Research and Enterprise Standard Operating Procedure Research Governance Title: Research Governance Audit SOP Reference Number: QUB-ADRE-08 Date prepared 7 August 008 Version Number: Final v -6.0 Revision
More informationTissue Viability Society. Strategy A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there...
Tissue Viability Society Tissue Viability Society Strategy 2017 2019 A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there... 1 CONTENTS OBJECTIVES 2 MISSION
More informationResearch Staff Training
REFERENCE: VERSION NUMBER: 3.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Research Infrastructure Manager REVIEWED BY: Research & Innovation Group APPROVED BY: Deputy Director of Research CONTROLLER:
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationERN Assessment Manual for Applicants
Share. Care. Cure. ERN Assessment Manual for Applicants 3.- Operational Criteria for the Assessment of Networks An initiative of the Version 1.1 April 2016 History of changes Version Date Change Page 1.0
More informationWork plan for GCP Inspectors Working Group for 2018
22 March 2018 EMA/87812 /2018 Committees and Inspections Chairperson: Ana Rodriguez The activities outlined in the work plan for 2018 have been agreed in view of preparation for the Agency s relocation
More informationCONDITIONS OF AWARD FOR ESA SCHOLARSHIPS AND FELLOWSHIPS
CONDITIONS OF AWARD FOR ESA SCHOLARSHIPS AND FELLOWSHIPS DATE CONTENTS Page 1. Application of conditions 2 2. Definitions 2 3. Award of scholarships and fellowships 2 4. Timing of scholarships and fellowships
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationSTH Researcher. Recording of research information in patient case notes
STANDARD OPERATING PROCEDURE STH Researcher Recording of research information in patient case notes SOP History None SOP Number A108 Created Research Department (AL) SUPERSEDED Final 1.3 Version 3.5 Date
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title SOP Index Number SOP 21 Version 4.0 Approval Date Effective Date Non-Compliance: Deviations and Serious Breaches of GCP and/or
More informationNational Research Ethics Service
National Research Ethics Service NRES Committee North West - Haydock HRA NRES Centre - Manchester 3rd Floor - Barlow House 4 Minshull Street Manchester M1 3DZ 16 May 2014 Telephone: 0161 625 7827 Facsimile:
More informationAddendum to ICH E6 (R2)
Addendum to ICH E6 (R2) Stephanie Shapley (US FDA) - Rapporteur Dr. Fergus Sweeney (EMA) - Regulatory Chair Date: December 15, 2015 International Council for Harmonisation of Technical Requirements for
More informationDocument Title: Investigator Site File. Document Number: 019
Document Title: Investigator Site File Document Number: 019 Version: 1.1 Ratified by: R&D Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title Safety Reporting and Pharmacovigilance SOP Index Number SOP 20 Version 4.0 Approval Date 31-Jan-2017 Effective Date 14-Feb-2017
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationCall title: Science in Society 2013
Call title: Science in Society 2013 Call identifier: FP7-SCIENCE-IN-SOCIETY-2013-1 Date of publication: 10 July 2012 Deadline 1 : 16 January 2013 at 17.00, Brussels local time. Indicative budget: 51.7
More informationWhy do we need an addendum to ICH E6?
Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in
More informationBRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER
BRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER Charter Effective Date: October 13, 2017 Release v2.0 Page 1 of 6 Introduction This Charter describes the roles and responsibilities
More informationGLOBAL WATER PARTNERSHIP POLICY ON PARTNERS
GLOBAL WATER PARTNERSHIP POLICY ON PARTNERS 1. Introduction This paper sets out the GWP Policy on Partners. It aims to clarify the concept and position of a Partner within the GWP. GWP has two categories
More informationConducting Monitoring Visits for Investigator-Initiated Trials (IITs)
Conducting Monitoring Visits for Investigator-Initiated Trials (IITs) Clinical Research Coordinator Society (CRCS) Forum 25 July 2014 Xia Yu Clinical Research Associate Singapore Clinical Research Institute
More informationReal World Evidence in Europe
Real World Evidence in Europe Jessamy Baird, RWE Director Madrid, 20 th October 2014. BEFORE I BEGIN; DISCLAIMERS: Dual perspective: Pharmaceutical: I work for Lilly, but this presentation represents my
More informationMEMBERSHIP PACK. ANZMUSC Executive Committee
MEMBERSHIP PACK ANZMUSC Executive Committee Professor Rachelle Buchbinder Professor Ian Harris AM Professor Chris Maher Professor Jane Latimer Professor Sally Green Professor Rana Hinman Associate Professor
More informationRisk Assessment. Version Number 1.0 Effective Date: 21 st March Sponsored Research
Risk Assessment Sponsored Research SOP Reference ID: Noclor/Spon/S03/01 Version Number 1.0 Effective Date: 21 st March 2016 It is the responsibility of all users of this SOP to ensure that the correct
More informationReport on Developed Tools for Joint Activities
Report on Developed Tools for Joint Activities June, 2015 1 Report on Developed Tools for Joint Activities D 7.1 Adele Manzella, CNR June, 2015 Publisher: Coordination Office, Geothermal ERA NET Orkustofnun,
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationEuropean Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS
European Medicines Agency Inspections London, 23 July 2008 EMEA/INS/GCP/197215/2005 Procedure no.: INS/GCP/3/V ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS GCP
More informationHigh Level Pharmaceutical Forum
High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following
More informationThe budget for this call is indicative. The final budget awarded to actions implemented through the call for proposals may vary:
CALL FICHE 1 SCIENCE IN SOCIETY 2011 Call identifier: FP7-SCIENCE-IN-SOCIETY-2011-1 Date of publication: Tuesday 20 July 2010 Deadline 1 : Thursday 20 January 2011 at 17.00.00, Brussels local time. Indicative
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationEUPATI PROJECT: EXECUTIVE SUMMARY
EUPATI PROJECT: EXECUTIVE SUMMARY Table of Contents 1 Overall objectives of EUPATI... 1 2 Results and successes of the EUPATI Project... 1 3 EUPATI s Future... 4 4 About this document... 5 1 Overall objectives
More informationPatient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force
5 May 2017 EMA/180341/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force EMA Initiative 1.
More informationR. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: BH/QMUL Sponsorship of CTIMPs, ATMPs and Clinical Trials of non- CE marked Medicinal Devices Process for Researchers SOP Number: 11a Version Number: V1.0 Effective
More information1 Abstract Calendar. 2 Submission Conditions. 3 Abstract Options. 4 Detailed Guidelines. 5 Abstract Corrections
ABSTRACT SUBMISSION 1 Abstract Calendar 2 Submission Conditions 3 Abstract Options 4 Detailed Guidelines 5 Abstract Corrections 6 Review 7 Registration of the Abstract Presenter 8 Presentation (E-posters)
More information1. INTRODUCTION 2. SCOPE 3. PROCESS
1. INTRODUCTION This document describes the procedure for establishing and maintaining records for staff training and complies with the principles of good clinical practice (GCP) for clinical trials of
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More informationPrinciples of "Good Scientific Practice" in the Federal Institute for Risk Assessment (BfR)
Version dated February 14, 2018 Principles of "Good Scientific Practice" in the Federal Institute for Risk Assessment (BfR) I. General To help meet its responsibility in research and the tasks directly
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationSTANDARD OPERATING PROCEDURE SOP 715. Principles of Clinical Research Laboratory Practice
STANDARD OPERATING PROCEDURE SOP 715 Principles of Clinical Research Laboratory Practice Version 1.2 Version date 13.11.2015 Effective date 24.04.2017 Number of pages 9 Review date June 2018 Author Role
More informationQuality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D
Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially
More informationCOUNCIL OF THE EUROPEAN UNION. Brussels, 16 June /08 COSDP 539
COUNCIL OF THE EUROPEAN UNION Brussels, 16 June 2008 10687/08 COSDP 539 NOTE from : European Union Military Staff to : European Union Military Committee No. prev. doc. : EUMC Mtg Doc 26/1/08 REV 1 Subject
More informationRegistry of Patient Registries (RoPR) Policies and Procedures
Registry of Patient Registries (RoPR) Policies and Procedures Version 4.0 Task Order No. 7 Contract No. HHSA290200500351 Prepared by: DEcIDE Center Draft Submitted September 2, 2011 This information is
More informationRetrospective Chart Review Studies
Retrospective Chart Review Studies Designed to fulfill requirements for real-world evidence Retrospective chart review studies are often needed in the absence of suitable healthcare databases and/or other
More informationIntellectual Property Rights and Marie Curie Actions: Essential at all stages of the project
Intellectual Property Rights and : Essential at all stages of the project Associate Professor Dr. Lidia Galabova Technical University of Sofia Consider the following documents: The Rules for Participation
More informationAbstract submission regulations and instructions
8 th European Lung Cancer Congress (ELCC) 11 14 April 2018, Geneva, Switzerland Abstract submission regulations and instructions Abstract submission deadline Late-breaking abstract deadline 8 January 2018
More informationGuidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products
Title: Identifier: Guidance For Health Care Staff Within NHS Grampian On Working With The Pharmaceutical Industry And Suppliers Of Prescribable Health Care Products NHSG/guid/PharmInd/GMMG/738 Replaces:
More informationDocument: Report on the work of the High Level Group in 2006
EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL HIGH LEVEL GROUP ON HEALTH SERVICES AND MEDICAL CARE Document: Report on the work of the High Level Group in 2006 Date: 10/10/2006 To:
More informationUK Cystic Fibrosis Registry. Data sharing policy
UK Cystic Fibrosis Registry Data sharing policy 1 Contents Introduction... 3 The UK Cystic Fibrosis Registry... 3 Governance... 3 Purpose... 3 Scope... 4 Policy... 4 Submitting a request... 4 Quality control...
More informationResearch & Development. Case Report Form SOP. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff
Department Title of SOP Research & Development Case Report Form SOP SOP reference no: R&D GCP SOP 03 Authors: Current version number and date: J H Pacynko and J Illingworth Version 2, 01.02.18 Next review
More informationRisk Assessment and Monitoring
Version 1.3 Effective date: 25 May 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 25 May 2012 Version 1.2 29 January 2010
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationDocument Title: Version Control of Study Documents. Document Number: 023
Document Title: Version Control of Study Documents Document Number: 023 Version: 1.1 Ratified by: Committee Date ratified: 03 OCT 2017 Name of originator/author: Directorate: Department: Name of responsible
More informationNEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationSubsidy contract for the project. Click here to enter text.
Subsidy contract for the project Click here to enter text. Version 02 as of 14.06.2016 The following contract between the Land of Salzburg acting as managing authority (hereinafter MA ) of the European
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationPatient Safety Curriculum Guide: Multi-professional Edition. Global Evaluation Study
Patient Safety Curriculum Guide: Multi-professional Edition Global Evaluation Study Content 1) Background and Rationale 2) Goals and Objectives 3) Evaluation Design 4) Dissemination of Results and Publication
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More information